DexCom, a glucose biosensing technology company, unveiled its proprietary Generative AI (GenAI) platform on Tuesday, December 17, becoming the first CGM manufacturer to integrate advanced AI into glucose biosensing technology. The new Dexcom GenAI platform leverages Google Cloud's Vertex AI and Gemini models to analyse individual health data, offering personalised insights that link lifestyle choices to glucose levels. This aims to help users make informed decisions to improve metabolic health, the company said.
Also Read: Nvidia and Partners Develop AI Model to Predict Future Glucose Levels in Individuals
Stelo GenAI Platform
Stelo, the first over-the-counter glucose biosensor FDA-cleared in the US, is the first Dexcom product to use GenAI technology to produce weekly insights. DexCom said the enhancement of Stelo's Weekly Insights feature began rolling out to users this week. GenAI-powered messaging enhances Stelo's existing Weekly Insights by providing users with more personalised tips, recommendations, and education related to diet, exercise, and sleep within the Stelo app, delivering actionable health recommendations.
GenAI-Powered Health Advancements
"The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio," said Jake Leach, executive vice president and chief operating officer at Dexcom. "Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualise their health information and make proactive, informed lifestyle decisions."
Also Read: Microsoft Announces New AI Models and Solutions for Healthcare
Leveraged Google Cloud Platform
DexCom said it leveraged Google Cloud's Vertex AI platform and Gemini models as the foundation for building its GenAI platform.
"By bringing the power of Google Cloud's Vertex AI and Gemini to Dexcom's innovative glucose biosensing technology, users will have more personalised insights to help them make the best decisions for their health," said Chris Sakalosky, vice president of Strategic Industries for Google Cloud. "Dexcom is empowering people to take control of their metabolic health like never before, and it's just the beginning of what's possible as leading organisations bring GenAI to healthcare."
Also Read: GE HealthCare Launches AI Innovation Lab to Drive Medical Advancements
Dexcom says the "proprietary platform lays the foundation for future GenAI advancements across the Dexcom product portfolio that will further empower its millions of users to help take control of their health."
